Celularity (CELU) Return on Capital Employed (2019 - 2025)
Celularity (CELU) posted quarterly Return on Capital Employed of 261.2% for Q4 2025, up 31097.0% year-over-year from N/an in Q4 2024, and up 379.59% quarter-over-quarter from 93.42% in Q3 2025.
Celularity (CELU) Return on Capital Employed (2019 - 2025) Analysis & Trends
Celularity (CELU) has reported Return on Capital Employed for 7 consecutive years, with 261.2% the latest figure, recorded in Q4 2025.
- In Q4 2025, Return on Capital Employed rose 31097.0% year-over-year to 261.2%; the TTM figure through Dec 2025 stood at 261.2% (up 31097.0% YoY), while the FY2025 annual figure was 430.23%, up 47557.0% from the prior year.
- Return on Capital Employed grew to 261.2% in Q4 2025 per CELU's latest filing, from 93.42% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 261.2% in Q4 2025 and bottomed at 231.0% in Q4 2023.
- Historically, Return on Capital Employed has averaged 49.82% across 5 years, with a median of 35.76% in 2021.
- Annual changes were most pronounced in 2023 — Return on Capital Employed tumbled 22383 bps — and 2025, when it soared 31097 bps.
- Celularity's Return on Capital Employed stood at 26.93% in 2021, then soared by 73 bps to 7.17% in 2022, then plunged by 3121 bps to 231.0% in 2023, then surged by 78 bps to 49.76% in 2024, then jumped by 625 bps to 261.2% in 2025.
- Business Quant data shows CELU's Return on Capital Employed at 261.2% in Q4 2025, 93.42% in Q3 2025, and 85.19% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.04 Bn | 130.18 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.98 Bn | 77.98 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.37 Bn | 59.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.67 Bn | 52.53 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.94 Bn | 36.84 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 27.75 Bn | 9.35 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.24 Bn | 26.08 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.03 Bn | 26.20 Bn | - | 7.88% |
| 10 | Celularity | 20.98 Mn | 14.81 Mn | -3.27 Mn | 261.20% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 261.20% |
| Sep 30, 2025 | -93.42% |
| Jun 30, 2025 | -85.19% |
| Mar 31, 2025 | -57.52% |
| Dec 31, 2024 | -49.76% |
| Sep 30, 2024 | -28.15% |
| Jun 30, 2024 | -144.23% |
| Mar 31, 2024 | -174.52% |
| Dec 31, 2023 | -231.00% |
| Sep 30, 2023 | -160.55% |
| Jun 30, 2023 | -39.47% |
| Mar 31, 2023 | -15.18% |
| Dec 31, 2022 | -7.17% |
| Sep 30, 2022 | -15.94% |
| Jun 30, 2022 | -10.40% |
| Mar 31, 2022 | -26.69% |
| Dec 31, 2021 | -26.93% |
| Sep 30, 2021 | -32.05% |
| Jun 30, 2021 | -48.68% |
| Mar 31, 2021 | -10.76% |